Fig. 1From: Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective studyTumor shrinkage rate in CNS target lesions; 11, 17, and 7 patients had CNS target lesions in these three cohorts respectively; median intracranial tumor shrinkage rate was 53% (range 0, 100%), 58% (range 14%, 100%), and 28% (range 0, 100%)Back to article page